Assertio Holdings

ASRT · NASDAQ

Price unavailable right now.

No price history for this range.

ASRT analyst rating

HoldConsensus of 2 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold2
Underperform0
Sell0

12-month price target · 5 analysts

Average $24.92

Low: $22.02
High: $29.40

Upgrades and downgrades

The latest rating actions, newest first

ASRT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	May 13, 2026	Maintains	Hold	$21.80 → $23.50	27%
HC Wainwright & Co.	May 5, 2026	Maintains	Neutral	$18.00 → $21.80	43%
Lake Street	Apr 9, 2026	Downgrade	Buy → Hold	$45.00 → $18.00	27%
HC Wainwright & Co.	Apr 9, 2026	Downgrade	Buy → Neutral	$35.00 → $18.00	43%
HC Wainwright & Co.	Jan 5, 2026	Maintains	Buy	$3.00 → $35.00	43%

The case for and against

Updated Jun 23, 2026

Bull case

Assertio Hldgs is well-positioned for growth in the pharmaceutical industry due to its diverse and differentiated product portfolio, with a particular focus on the high-demand oncology market. The company's strong commercial capabilities allow it to effectively market and sell its products, leading to steady revenue growth and strong financial performance. As a result, the positive outlook for Assertio Hldgs is supported by its reliable revenue streams and potential for continued expansion in the future.

Bear case

Assertio Hldgs is in a significant shift phase, as it recently agreed to be acquired by Garda Therapeutics for $18 per share. This is a 34.6% premium to the company's unaffected stock price on March 20, 2026, and a 46.6% premium to the 30-day unaffected volume-weighted average price (VWAP). The deal was unanimously approved by both companies' boards, with the potential for a CVR tied to future milestones for a legacy product with low revenue potential. Due to this significant shift and limited upside potential, the analyst downgraded their rating on the stock to Neutral with a revised price target of $18 per share.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.